Veracyte Inc (NASDAQ:VCYT)
| 34.64 Delayed Data As of Oct 30 |  -2.17 / -5.90%Today’s Change | 13.90 Today|||52-Week Range 44.64 | +24.07% Year-to-Date |
Latest VCYT News | Press Releases
| Analysts Estimate Veracyte (VCYT) to Report a Decline in Earnings: What to Look Out for Oct 26 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 36.81 |
| Today’s open | 37.30 |
| Day’s range | 33.85 - 38.07 |
| Volume | 19,668 |
| Average volume (3 months) | 554,965 |
| Market cap | $2.1B |
Data as of 3:59pm ET, 10/30/2020
Growth & Valuation
| Earnings growth (last year) | +56.04% |
| Earnings growth (this year) | -198.77% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +30.82% |
| P/E ratio | NM |
| Price/Sales | 10.70 |
| Price/Book | 7.53 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CDNACareDx Inc | -2.06 | -4.03% |
| TRILTrillium Therapeutic... | -0.37 | -2.89% |
| MYGNMyriad Genetics Inc | -0.63 | -4.82% |
| VIVOMeridian Bioscience ... | -2.26 | -11.64% |
Data as of 4:00pm ET, 10/30/2020
Financials
| Next reporting date | November 3, 2020 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $120.4M |
| Annual profit (last year) | -$12.6M |
| Net profit margin | -10.47% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters South San Francisco, California |
Forecasts
